Back to Search
Start Over
Elevated plasma level of the glycolysis byproduct methylglyoxal on admission is an independent biomarker of mortality in ICU COVID-19 patients.
- Source :
- Scientific Reports; 6/9/2022, Vol. 12 Issue 1, p1-22, 22p
- Publication Year :
- 2022
-
Abstract
- Biomarkers to identify ICU COVID-19 patients at high risk for mortality are urgently needed for therapeutic care and management. Here we found plasma levels of the glycolysis byproduct methylglyoxal (MG) were 4.4-fold higher in ICU patients upon admission that later died (n = 33), and 1.7-fold higher in ICU patients that survived (n = 32),compared to uninfected controls (n = 30). The increased MG in patients that died correlated inversely with the levels of the MG-degrading enzyme glyoxalase-1 (r<superscript>2</superscript> = − 0.50), and its co-factor glutathione (r<superscript>2</superscript> = − 0.63), and positively with monocytes (r<superscript>2</superscript> = 0.29). The inflammation markers, SSAO (r<superscript>2</superscript> = 0.52), TNF-α (r<superscript>2</superscript> = 0.41), IL-1β (r<superscript>2</superscript> = 0.25), CRP (r<superscript>2</superscript> = 0.26) also correlated positively with MG. Logistic regression analysis provides evidence of a significant relationship between the elevated MG upon admission into ICU and death (P < 0.0001), with 42% of the death variability explained. From these data we conclude that elevated plasma MG on admission is a novel independent biomarker that predicts mortality in ICU COVID-19 patients. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 20452322
- Volume :
- 12
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Scientific Reports
- Publication Type :
- Academic Journal
- Accession number :
- 157413640
- Full Text :
- https://doi.org/10.1038/s41598-022-12751-y